Oddo BHF - Cegedim SA (CGM) Cegedim : CA S1 2020, bonne rÃ©sistance de lâ€™organique

Report

Oddo BHF

Geoffroy Michalet

Cegedim : CA S1 2020, bonne rÃ©sistance de lâ€™organique

>CA S1Â : plutÃ´t de bonne facture - Cegedim a publiÃ© hier soir son CA T2 et S1, plutÃ´t de bonne facture. Alors que nous attendions un S1 en baisse organique de -2.0%, il ressort Ã -2.5% org, et -3.9% en publiÃ©, notamment avec un effet pÃ©rimÃ¨tre de -1.4% du fait de la cession de Pulse aux USA (mÃ©decins) et des acquisitions de NetEDI (E-Business) et Cosytec (RH). Le FX nâ€™a pas dâ€™impact sur le semestrePar divisionÂ :Health Insurance, HR & E-Services (68% du CA) :...

29/07/2020 4 FR

Underlying

Cegedim SA

Cegedim is a technology and services company. Co. supplies services, IT tools, specialized software, information flow and database management services to healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies. Co.'s operations can be divided into three sectors: CRM and Strategic Data (optimizing marketing and sales strategies, namely through tools and databases for managing sales forces, returns on investment, market or prescriber studies); Healthcare Professionals (software publishing with availability of promotional information) and Insurance and Services (software publishing and management of healthcare reimbursement flows).

See profile

FR0000053506 Euronext Paris France

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Geoffroy Michalet

Other Reports on these Companies

SmartInsider

Cegedim: 1 director

A director at Cegedim bought 20,655 shares at 13.849EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Free Trial

April 18, 2024 April 18, 2024 1 EN

GlobeNewsWire

Cegedim: Release of its 2023 Universal Registration Document

Cegedim: Release of its 2023 Universal Registration Document PRESS RELEASE Financial Information Cegedim: Release of its 2023 Universal Registration Document Boulogne-Billancourt, April 4, 2024 , an innovative technology and services company, announces that its 2023 Universal Registration Document (in French) has been published in compliance with Autorité des Marchés Financiers (AMF) regulations on April 3, 2024, under the number: D.24-0233. The report is available free of charge: At the company headquarters Cegedim, Financial Department, 137 rue d’Aguesseau, 92100 B...

April 4, 2024 April 4, 2024 1 EN

Oddo BHF

ODDO BHF Small & MIDCAP MORNING NEWS - 03/28/2024

With the exception of the US, construction markets should continue to shrink in 2024 (-2% in Europe) before rebounding on the back of lower interest rates. Against this backdrop, groups will be differentiated mainly on the basis of their resilience (geographical and price/cost mix), capital allocation (and special situations) and valuation. In this context, we are upgrading our recommendations on KONE (modernisation as an alternative source of growth to China) and Holcim (a substantia...

March 28, 2024 March 28, 2024 1 EN

AstraZeneca : Un T1 extrêmement rassurant confirmant les ambitions 2024

>Symbicort et Farxiga mènent la danse - AZN vient de publier ses résultats du T1 24 qui se révèlent nettement supérieurs aux attentes du fait notamment de Farxiga et Symbicort. Les revenus sont en hausse de 19% à tcc tirés par sa franchise CVRM (cardio metabolique) et Oncologie. Les ventes ressortent ainsi 7% au-dessus des attentes. Bien que pénalisée par une baisse de prix récentes de Tagrisso (Juin 23), Imfinzi (Fevr 24) et Faslodex en Chine (Nov 23), la Chine est e...

1h / 6m 1h / 6m 1 FR

Nicolas David

Nicolas David

Dassault Systemes : Mixed Q1 earnings but satisfactory Q2 guidance and FY 2024 guidance reiterated

>Q1 2024 earnings roughly in line: slightly below at topline level, impacted by Medidata slower growth, but above at EPS level - Total revenue came to € 1,500m up 5% on a reported basis and 6% at cc /org. This is -1% below expectations in reported terms and -2pts below at cc (ODDO BHF: € 1518m, up 8.0% cc; Css: € 1,512m up 7.9% at cc). This performance is below the lower end of the guidance (7% to 8% at cc) notably due to Services revenue up only 2% cc). Software...

1h / 6m 1h / 6m 1 EN

Pierre Tegner

Pierre Tegner

Unilever PLC : A good, high quality start to the year: +2.2% volume/mix and +2.2% price

>Q1 sales 2% above expectations - Q1 sales at € 14,963m were up +1.4% (vs cons. at -0.7%) with a forex effect of -2% (vs css at -3% ), a scope impact of -0.9% and organic growth of 4.4% vs the consensus at 2.9%.The outlook for 2024 is confirmed with 3% to 5% l-f-l, moderate margin improvement. The CEO highlighted increasing confidence in accelerating gross margin expansion and delivering sustained volume growth and a positive mix. On ice cream and the sepa...

1h / 7m 1h / 7m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Cegedim : CA S1 2020, bonne rÃ©sistance de lâ€™organique

Cegedim: 1 director

Cegedim: Release of its 2023 Universal Registration Document

ODDO BHF Small & MIDCAP MORNING NEWS - 03/28/2024

AstraZeneca : Un T1 extrêmement rassurant confirmant les ambitions 2024

Dassault Systemes : Mixed Q1 earnings but satisfactory Q2 guidance and FY 2024 guidance reiterated

Unilever PLC : A good, high quality start to the year: +2.2% volume/mix and +2.2% price

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe